Diabetes mellitus a kardiovaskulární onemocnění
| Title in English | Diabetes mellitus and cardiovascular disease |
|---|---|
| Authors | |
| Year of publication | 2018 |
| Type | Article in Periodical |
| Magazine / Source | Kardiologická revue - Interní medicína |
| MU Faculty or unit | |
| Citation | |
| Description | SGLT2 inhibitors - gliflozins were introduced into clinical practice as oral antidiabetics, acting by increased glucose excretion by urine using the blockade of SGLT2 co-transporter, which leads to the blocking of glucose reabsorption in the kidneys. The first big clinical trial EMPA-REG OUTCOME has shown not only their effect on diabetes mellitus but also the effect of decreasing cardiovascular events, especially heart failure mortality and hospitalisations. The results also suggest that SGLT2 inhibitors have led to a decrease in body weight by 2-3 kg and to a decrease of systolic blood pressure by 3-5 mm Hg. The CANVAS trials presented in 2017 confirmed this beneficial effect on the decrease of hospitalization from heart failure and reduction of CV events. Real life data - obtained in the CVD REAL research on more than 300,000 patients from all over the world - confirm the positive results obtained in clinical trials. |